Skip to content

Xenon Pharmaceuticals XENE Free cash flow margin

Free cash flow margin at other companies

Eli Lilly logo
Eli LillyLLY
16.4%+8.7pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.5%-4.3pp
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
28.6%-8.6pp
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-10.2%-3.9pp
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-3,067.4%-1,030pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
26.8%+6.4pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$112.3M-54.4%
Net income-$102.3M-57.3%
EPS (diluted)-$1.17-41.0%

Balance sheet

See full
Cash & equivalents$545.9M+368%
Total debt$7.5M-13.6%
Total equity$1.3B+90.0%
Total assets$1.4B+86.6%

Cash flow

See full
Operating cash flow-$88.9M-44.2%
CapEx$133.0K+209%
Free cash flow-$89.0M-44.3%

Valuation

See full
Market cap$5.11B+116%
Enterprise value$4.58B+104%

Profitability

See full
Operating margin-4,974.3%
Net margin-4,612.1%

Returns & leverage

See full
Return on equity-37.5%+8.7pp
Debt / equity0.0×
Current ratio27.8×+10.1×

Where this comes from

Calculated from Xenon Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xenon Pharmaceuticals's free cash flow margin?
Xenon Pharmaceuticals (XENE) reported free cash flow margin of -3,732.2% in Q4 2025.
What is the long-term trend for Xenon Pharmaceuticals's free cash flow margin?
Over 3 years (2020 to 2025), Xenon Pharmaceuticals's free cash flow margin has grown at a 187.0% compound annual growth rate (CAGR), from -157.8% to -3,732.2%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.